A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia
| Autor: | Michael J. Detke, Sharon Rosenzweig-Lipson, Janet B. W. Williams, Earl L. Giller, John M. Kane, Joan H.Q. Shen, Danielle Popp, Yonggang Zhao |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male Olanzapine Vabicaserin Placebo Heterocyclic Compounds 4 or More Rings Young Adult Double-Blind Method medicine Clinical endpoint Humans Biological Psychiatry Psychiatric Status Rating Scales Analysis of Variance Dose-Response Relationship Drug Middle Aged medicine.disease Clinical trial Psychiatry and Mental health Treatment Outcome Tolerability Schizophrenia Anesthesia Acute Disease Female medicine.symptom Psychology Weight gain Antipsychotic Agents medicine.drug |
| Zdroj: | Journal of Psychiatric Research. 53:14-22 |
| ISSN: | 0022-3956 0026-5551 |
| Popis: | Vabicaserin, a potent 5-HT2C receptor agonist, decreases nucleus accumbens extracellular dopamine levels in rats, without affecting striatal dopamine, indicating mesolimbic selectivity. This is the first study of efficacy, safety and tolerability of vabicaserin in adults with acute schizophrenia. Three hundred fourteen hospitalized subjects were randomized to: Vabicaserin 200 or 400 mg/day, olanzapine 15 mg/day or placebo. Central raters assessed the PANSS and CGI-S. Site raters performed the BPRS and CGI-I. Central rated PANSS Positive (PANSS-PPS) was the primary endpoint. Two hundred eighty-nine subjects were included in the mITT efficacy analysis. Vabicaserin was well tolerated with no major safety concerns. Olanzapine, but not vabicaserin, caused weight gain. Vabicaserin 200 mg/day and olanzapine demonstrated significant improvement at week 6 vs. placebo on PANSS-PSS. A non-significant decrease vs. placebo was observed for 400 mg/day. Both vabicaserin groups demonstrated significant improvement over baseline on PANSS Negative while placebo worsened. Vabicaserin 200 mg/day and olanzapine demonstrated significantly greater improvement over placebo on PANSS Total whereas 400 mg/day showed a trend toward improvement. There was no significant improvement vs. placebo for either vabicaserin group on site-rated BPRS. Vabicaserin 200 mg/day and olanzapine demonstrated significant improvement vs. placebo on CGI-I and CGI-S but not 400 mg/day vabicaserin. Vabicaserin demonstrated efficacy on primary and secondary endpoints at 200 mg/day, but not at 400 mg/day which showed a trend for efficacy. The 200 mg/day vabicaserin group achieved proof of concept using central ratings. Both vabicaserin doses were well tolerated with no significant safety signals and no weight gain. Trial Registration: clinicaltrials.gov. Identifier: NCT00265551. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect